detection of methylated sept9 in plasma is a reliable screening method for both left- and right-sided colon cancers检测甲基化sept9在等离子体是一种可靠的检查方法,同时具有左、右侧结肠癌.pdfVIP

下载本文档

3
0
约5.46万字
约 7页
2017-09-12 发布于上海
举报
版权申诉

detection of methylated sept9 in plasma is a reliable screening method for both left- and right-sided colon cancers检测甲基化sept9在等离子体是一种可靠的检查方法,同时具有左、右侧结肠癌.pdf

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

detection of methylated sept9 in plasma is a reliable screening method for both left- and right-sided colon cancers检测甲基化sept9在等离子体是一种可靠的检查方法,同时具有左、右侧结肠癌

Detection of Methylated SEPT9 in Plasma Is a Reliable Screening Method for Both Left- and Right-Sided Colon Cancers ´ 1 1 ´ 1 ´ ´ 1 ´ 2 3 Kinga Toth *, Ferenc Sipos , Alexandra Kalmar , Arpad V. Patai , Barnabas Wichmann , Robert Stoehr , 4 4 1,2 ´ ´ 1,2 Henriette Golcher , Vera Schellerer , Zsolt Tulassay , Bela Molnar 1 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary, 2 Molecular Medicine Research Unit, Hungarian Academy of Sciences, Budapest, ¨ ¨ Hungary, 3 Institute for Pathology, Universitatsklinikum Erlangen, Erlagen, Germany, 4 Department of Surgery, Universitatsklinikum Erlangen, Erlagen, Germany Abstract Background: Methylated Septin 9 (SEPT9) is a sensitive biomarker for colorectal cancer (CRC) from peripheral blood. However, its relationship to cancer localization, guaiac-based fecal occult blood test (gFOBT) and carcinoembryonic antigen (CEA) have not been described. Methodology/Principal Findings: Plasma samples were collected for SEPT9 analysis from patients with no evidence of disease (NED) (n = 92) before colonoscopy and CRC (n = 92) before surgical treatment. DNA was isolated and bisulfite- converted using Epi proColon kit 2.0. Qualitative determination was performed using Epi proColon 2.0 RT-PCR assay. Samples for gFOBT and CEA analysis were collected from NED (n = 17 and 27, respectively) and CRC (n = 22 and 27, respectively). SEPT9 test was posi